The diagnostic and therapeutic approach to prostate cancer has evolved rapidly in last decades. Young professionals need an update about these recent developments in order to improve the care of patients treated in their daily clinical practice.
Methods
On May 18, 2013, AIRO Giovani (the young section of the Italian Association of Radiation Oncology) organized a multidisciplinary meeting involving, as speakers, several young physicians from many parts of Italy actively involved in the diagnostic and therapeutic approach to prostate cancer. The meeting was specifically addressed to young physicians (radio-oncologists, urologists, medical oncologists) and presented the state-of-the-art of the diagnostic/therapeutic approach based on the latest evidence on the issue. Highlights of the congress are summarized and presented in this report.
Results
The large participation in the meeting (more than 120 participants were present) confirmed the interest of young radiation oncologists in improving their skills in prostate cancer management. The contributions of the speakers confirmed the need for regular updates, considering the promising results of recently published studies and the many new ongoing trials, on the diagnostic and therapeutic approaches to prostate cancer.
Conclusions
Multidisciplinary meetings are helpful to improve the skills of young professionals.
MunozF., FiandraC., FrancoP., GuarneriA., CiammellaP., De StefanisP., RondiN., MorettoF., BadellinoS., IftodeC., RagonaR., RicardiU.: Tracking target position variability using intraprostatic fiducial markers and electronic portal imaging in prostate cancer radiotherapy. Radiol Med, 117: 1057–1070, 2012.
4.
UdrescuC., De BariB., RouvièreO., RuffionA., Michel-AmadryG., JaladeP., DevonecM., ColombelM., ChapetO.: Does hormone therapy modify the position of the gold markers in the prostate during irradiation? A daily evaluation with kV-images. Cancer Radiother, 17: 215–220, 2013.
5.
ArcangeliS., ScorsettiM., AlongiF.: Will SBRT replace conventional radiotherapy in patients with low-intermediate risk prostate cancer? A review. Crit Rev Oncol Hematol, 84: 101–108, 2012.
6.
CloseA., RobertsonC., RushtonS., ShirleyM., ValeL., RamsayC., PickardR.: Comparative cost-effectiveness of robot-assisted and standard laparoscopic prostatectomy as alternatives to open radical prostatectomy for treatment of men with localised prostate cancer: a health technology assessment from the perspective of the UK National Health Service. Eur Urol, 64: 361–369, 2013.
7.
AlvaA., HussainM.: The changing natural history of metastatic prostate cancer. Cancer J, 19: 19–24, 2013.
8.
AlongiF., De BariB., FrancoP., CiammellaP., ChekrineT., LiviL., Jereczek-FossaB.A., FilippiA.R.; on behalf of AIRO Young and AIRO Prostate cancer Working Group: The PROCAINA (PROstate CAncer INdication Attitudes) Project (Part I): a survey among Italian radiation oncologists on postoperative radiotherapy in prostate cancer. Radiol Med, 118: 660–678, 2013.
9.
De BariB., AlongiF., FrancoP., CiammellaP., ChekrineT., LiviL., Jereczek-FossaB.A., FilippiA.R.; on behalf of AIRO Young and AIRO Prostate cancer Working Group: The “PROCAINA (PROstate CAncer INdication Attitudes) Project” (Part II) - A survey among Italian radiation oncologists on radical radiotherapy in prostate cancer. Radiol Med, 118: 1220–1229, 2013.
10.
FilippiA.R., AlongiF., CiammellaP., De BariB., FrancoP., LiviL.: A strategy for young members within national radiation oncology societies: The Italian experience (AIRO Giovani group). Rep Pract Oncol Radiother, 17: 259–261, 2012.
11.
De BariB., ChiesaS., FilippiA.R., GambacortaM.A., D'EmilioV., MurinoP., LiviL.; AIRO (Italian Association of Radiation Oncology) and the AIRO Palliative Care Group: The INTER-ROMA project- a survey among Italian radiation oncologists on their approach to the treatment of bone metastases. Tumori, 97: 177–184, 2011.
12.
PegurriL., BuglioneM., GirelliG., GuarneriA., MeattiniI., RicardiU., MangoniM., GabrieleP., BellavitaR., KrengliM., BonettaA., CagnaE., BunkheilaF., BorghesiS., SignorM., Di MarcoA., BertoniF., StefanacciM., GattaR., De BariB., MagriniS.: Changes in patterns of practice for prostate cancer radiotherapy in Italy 1995–2003. A survey of the Prostate Cancer Study Group of the Italian Radiation Oncology Society (AIRO). Tumori 2014, in press.
13.
FerlayJ., Steliarova-FoucherE., Lortet-TieulentJ., RossoS., CoeberghJ.W., ComberH., FormanD., BrayF.: Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer, 49: 1374–1403, 2013.
14.
Bill-AxelsonA., HolmbergL., RuutuM., GarmoH., StarkJ.R., BuschC., NordlingS., HäggmanM., AnderssonS.O., BratellS., SpångbergA., PalmgrenJ., SteineckG., AdamiH.O., JohanssonJ.E.; SPCG-4 Investigators: Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med, 364: 1708–1717, 2011.
15.
WiltT.J., BrawerM.K., JonesK.M., BarryM.J., AronsonW.J., FoxS., GingrichJ.R., WeiJ.T., GilhoolyP., GrobB.M., NsouliI., IyerP., CartagenaR., SniderG., RoehrbornC., SharifiR., BlankW., PandyaP., AndrioleG.L., CulkinD., WheelerT.; Prostate Cancer Intervention versus Observation Trial (PIVOT) Study Group: Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med, 367: 203–213, 2012.
16.
BastianP.J., CarterB.H., BjartellA., SeitzM., StanislausP., MontorsiF., StiefC.G., SchröderF.: Insignificant prostate cancer and active surveillance: from definition to clinical implications. Eur Urol, 55: 1321–1330, 2009.
17.
BulM., ZhuX., ValdagniR., PicklesT., KakehiY., RannikkoA., BjartellA., van der SchootD.K., CornelE.B., ContiG.N., BoevéE.R., StaermanF., Vis-MatersJ.J., VergunstH., JasparsJ.J., Strö-linP., van MuilekomE., SchröderF.H., BangmaC.H., RoobolM.J.: Active surveillance for low-risk prostate cancer worldwide: the PRIAS study. Eur Urol, 63: 597–603, 2013.
18.
KlotzL.: active surveillance for prostate cancer: a Review. Curr Urol Rep, 11: 165–171, 2010.
19.
BellarditaL., RancatiT., AlvisiM.F., VillaniD., MagnaniT., MarenghiC., NicolaiN., ProcopioG., VillaS., SalvioniR., ValdagniR.: Predictors of health-related quality of life and adjustment to prostate cancer during active surveillance. Eur Urol, 64: 30–36, 2013.
20.
AizerA.A., PalyJ.J., ZietmanA.L., NguyenP.L., BeardC.J., RaoS.K., KaplanI.D., NiemierkoA., HirschM.S., WuC.L., OlumiA.F., MichaelsonM.D., D'AmicoA.V., EfstathiouJ.A.: Multidisciplinary care and pursuit of active surveillance in low-risk prostate cancer. J Clin Oncol, 30: 3071–3076, 2012.
21.
MagnaniT., ValdagniR., SalvioniR., VillaS., BellarditaL., DoneganiS., NicolaiN., ProcopioG., BediniN., RancatiT., ZaffaroniN.: The 6-year attendance of a multidisciplinary prostate cancer clinic in Italy: incidence of management changes. BJU Int, 110: 998–1003, 2012.
22.
Lu-YaoG.L., AlbertsenP.C., MooreD.F., ShihW., LinY., DiPaolaR.S., YaoS.L.: Survival following primary androgen deprivation therapy among men with localized prostate cancer. JAMA, 300: 173–181, 2008.
23.
Lu-YaoG.L., AlbertsenP.C., LiH., MooreD.F., ShihW., LinY., DiPaolaR.S., YaoS.L.: Does primary androgen-deprivation therapy delay the receipt of secondary cancer therapy for localized prostate cancer?Eur Urol, 62: 966–972, 2012.
24.
IversenP., McLeodD.G., SeeW.A., MorrisT., ArmstrongJ., WirthM.P.; Casodex Early Prostate Cancer Trialists' Group: Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide Early Prostate Cancer programme at a median follow-up of 9.7 years. BJU Int, 105: 1074–1081, 2010.
25.
BarentszJ.O., RichenbergJ., ClementsR., ChoykeP., VermaS., VilleirsG., RouviereO., LogagerV., FüttererJ.J.; European Society of Urogenital Radiology: ESUR prostate MR guidelines 2012. Eur Radiol, 22: 746–757, 2012.
26.
TanimotoA., NakashimaJ., KohnoH., ShinmotoH., KuribayashiS.: Prostate cancer screening: the clinical value of diffusion weighted imaging and dynamic MR imaging in combination with T2-weighted imaging. J Magn Reson Imaging, 25: 146–152, 2007.
27.
AkinO., SalaE., MoskowitzC.S., KuroiwaK., IshillN.M., PucarD., ScardinoP.T., HricakH.: Transition zone prostate cancers: features, detection, localization, and staging at endorectal MR imaging. Radiology, 239: 784–792, 2006.
28.
YoshizakoT., WadaA., HayashiT., UchidaK., SumuraM., UchidaN., KitagakiH., IgawaM.: Usefulness of diffusion-weighted imaging and dynamic contrast-enhanced magnetic resonance imaging in the diagnosis of prostate transition-zone cancer. Acta Radiol, 49: 1207–1213, 2008.
29.
KitajimaK., KajiY., FukaboriY., YoshidaK., SuganumaN., SugimuraK.: Prostate cancer detection with 3T MRI: comparison of diffusion-weighted imaging and dynamic contrast-enhanced MRI in combination with T2-weighted imaging. J Magn Reson Imaging, 31: 625–631, 2010.
30.
FüttererJ.J., HeijminkS.W., ScheenenT.W., VeltmanJ., HuismanH.J., VosP., Hulsbergen-Van de KaaC.A., WitjesJ.A., KrabbeP.F., HeerschapA., BarentszJ.O.: Prostate cancer localization with dynamic contrast enhanced MR imaging and proton MR spectroscopic imaging. Radiology, 241: 449–458, 2006.
31.
CirilloS., PetracchiniM., ScottiL., GalloT., MaceraA., BonaM.C., OrtegaC., GabrieleP., ReggeD.: Endorectal magnetic resonance imaging at 1.5 Tesla to assess local recurrence following radical prostatectomy using T2-weighted and contrast-enhanced imaging. Eur Radiol, 19: 761–769, 2009.
32.
HaiderM.A., ChungP., SweetJ., ToiA., JhaveriK., MénardC., WardeP., TrachtenbergJ., LockwoodG., MilosevicM.: Dynamic contrast-enhanced magnetic resonance imaging for localization of recurrent prostate cancer after external beam radiotherapy. Int J Radiat Oncol Biol Phys, 70: 425–430, 2008.
33.
van AsN.J., de SouzaN.M., RichesS.F., MorganV.A., SohaibS.A., DearnaleyD.P., ParkerC.C.: A study of diffusion-weighted magnetic resonance imaging in men with untreated localised prostate cancer on active surveillance. Eur Urol, 56: 981–987, 2009.
34.
ItouY., NakanishiK., NarumiY., NishizawaY., TsukumaH.: Clinical utility of apparent diffusion coefficient (ADC) values in patients with prostate cancer: can ADC values contribute to assess the aggressiveness of prostate cancer?J Magn Reson Imaging, 33: 167–172, 2011.
35.
HambrockT., HuismanH.J., van OortI.M., van OortI.M., WitjesJ.A., Hulsbergen-van de KaaC.A., ScheenenT., BarentszJ.O.: Relationship between apparent diffusion coefficients at 3.0-T MR imaging and Gleason grade in peripheral zone prostate cancer. Radiology, 259: 453–461, 2011.
KurhanewiczJ., VigneronD., CarrollP., CoakleyF.: Multiparametric magnetic resonance imaging in prostate cancer: present and future. Curr Opin Urol, 18: 71–77, 2008.
38.
VilleirsG.M., De MeerleerG.O., De VisschereP.J., FonteyneV.H., VerbaeysA.C., OosterlinckW.Combined magnetic resonance imaging and spectroscopy in the assessment of high grade prostate carcinoma in patients with elevated PSA: a single-institution experience of 356 patients. Eur J Radiol, 77: 340–345, 2011.
39.
SciarraA., PanebiancoV., SalcicciaS., OsimaniM., LisiD., CiccarielloM., PassarielloR., Di SilverioF., GentileV.: Role of dynamic contrast-enhanced magnetic resonance (MR) imaging and proton MR spectroscopic imaging in the detection of local recurrence after radical prostatectomy for prostate cancer. Eur Urol, 54: 589–600, 2008.
40.
De VisschereP.J., De MeerleerG.O., FuttererJ.J., VilleirsG.M.: Role of MRI in follow-up after focal therapy for prostate carcinoma. Am J Roentgenol, 194: 1427–1433, 2010.
KrauseB.J., SouvatzoglouM., TreiberU.: Imaging of prostate cancer with PET/CT and radioactively labeled choline derivates. Urol Oncol, 31: 427–435, 2013.
43.
UmbehrM.H., MüntenerM., HanyT., SulserT., BachmannL.M.: The Role of 11C-choline and 18F-fluorocholine positron emission tomography (PET) and PET/CT in prostate cancer: a systematic review and meta-analysis. Eur Urol, 64: 106–117, 2013.
44.
SouvatzoglouM., WeirichG., SchwarzenboeckS., MaurerT., SchusterT., BundschuhR.A., EiberM., HerrmannK., KueblerH., WesterH.J., HoeflerH., GschwendJ., SchwaigerM., TreiberU., KrauseB.J.: The sensitivity of [11C]choline PET/CT to localize prostate cancer depends on the tumor configuration. Clin Cancer Res, 17: 3751–3759, 2011.
45.
BeheshtiM., ImamovicL., BroingerG., ValiR., WaldenbergerP., StoiberF., NaderM., GruyB., JanetschekG., LangstegerW.: 18F choline PET/CT in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: a prospective study of 130 patients. Radiology, 254: 925–933, 2010.
46.
SoykaJ.D., MusterM.A., SchmidD.T., SeifertB., SchickU., MiralbellR., JorcanoS., ZauggK., SeifertH.H., Veit-HaibachP., StrobelK., SchaeferN.G., HusarikD.B., HanyT.F.: Clinical impact of 18F-choline PET/CT in patients with recurrent prostate cancer. Eur J Nucl Med Mol Imaging, 39: 936–943, 2012.
47.
CastellucciP., FuccioC., NanniC., SantiI., RizzelloA., LodiF., FranceschelliA., MartoranaG., ManferrariF., FantiS.: Influence of trigger PSA and PSA kinetics on 11C-choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy. J Nucl Med, 50: 1394–1400, 2009.
48.
KrauseB.J., SouvatzoglouM., TuncelM., HerrmannK., BuckA.K., PrausC., SchusterT., GeinitzH., TreiberU., SchwaigerM.: The detection rate of [11C]choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer. Eur J Nucl Med Mol Imaging, 35: 18–23, 2008.
49.
PicchioM., BrigantiA., FantiS., HeidenreichA., KrauseB.J., MessaC., MontorsiF., ReskeS.N., ThalmannG.N.: The role of choline positron emission tomography/computed tomography in the management of patients with prostate-specific antigen progression after radical treatment of prostate cancer. Eur Urol, 59: 51–60, 2011.
50.
CastellucciP., FuccioC., RubelloD., SchiavinaR., SantiI., NanniC., AllegriV., MontiniG.C., AmbrosiniV., BoschiS., MartoranaG., MarzolaM.C., FantiS.: Is there a role for 11C-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase <1.5 ng/ml?Eur J Nucl Med Mol Imaging, 38: 55–63, 2011.
51.
GiovacchiniG., PicchioM., ParraR.G., BrigantiA., GianolliL., MontorsiF., MessaC.: Prostate-specific antigen velocity versus prostate-specific antigen doubling time for prediction of 11C choline PET/CT in prostate cancer patients with biochemical failure after radical prostatectomy. Clin Nucl Med, 37: 325–331, 2012.
52.
DostR.J., GlaudemansA.W., BreeuwsmaA.J., de JongI.J.: Influence of androgen deprivation therapy on choline PET/CT in recurrent prostate cancer. Eur J Nucl Med Mol Imaging, 40 Suppl 1: 41–47, 2013.
53.
GiovacchiniG.: Do we have to withdraw antiandrogenic therapy in prostate cancer patients before PET/CT with [11C]choline?Eur J Nucl Med Mol Imaging, 38: 1964–1966, 2011.
54.
HeidenreichA., BellmuntJ., BollaM., JoniauS., MasonM., MatveevV., MottetN., SchmidH.P., van der KwastT., WiegelT., ZattoniF.; European Association of Urology: EAU guidelines on prostate cancer. Part 1: Screening, diagnosis, and treatment of clinically localised disease. Eur Urol, 59: 61–71, 2011.
55.
BrigantiA., SpahnM., JoniauS., GonteroP., BianchiM., KneitzB., ChunF.K., SunM., GraefenM., AbdollahF., MarchioroG., FrohenbergD., GionaS., FreaB., KarakiewiczP.I., MontorsiF., Van PoppelH., Jeffrey KarnesR.; European Multicenter Prostate Cancer Clinical and Translational Research Group (EMPaCT): Impact of age and comorbidities on long-term survival of patients with high-risk prostate cancer treated with radical prostatectomy: a multi-institutional competing-risks analysis. Eur Urol, 63: 693–701, 2013.
56.
MottetN., BellmuntJ., BollaM., JoniauS., MasonM., MatveevV., SchmidH.P., Van der KwastT., WiegelT., ZattoniF., HeidenreichA.: EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol, 59: 572–583, 2011.
57.
BellmuntJ., AttardG., BahlA., HulandH., KlotzL., KubanD., OudardS., WatsonW.: Advances in the management of high-risk localised and metastatic prostate cancer. BJU Int, 109 Suppl 2: 8–13, 2012.
58.
HatibogluG., TeberD., HohenfellnerM.: Robot-assisted prostatectomy: the new standard of care. Langenbecks Arch Surg, 397: 343–352, 2012.
WillisD.L., GonzalgoM.L., BrotzmanM., FengZ., TrockB., SuL.M.: Comparison of outcomes between pure laparoscopic vs robot-assisted laparoscopic radical prostatectomy: a study of comparative effectiveness based upon validated quality of life outcomes. BJU Int, 109: 898–905, 2012.
61.
TewariA., SooriakumaranP., BlochD.A., Seshadri-KreadenU., HebertA.E., WiklundP.: Positive surgical margin and perioperative complication rates of primary surgical treatments for prostate cancer: a systematic review and meta-analysis comparing retropubic, laparoscopic, and robotic prostatectomy. Eur Urol, 62: 1–15, 2012.
62.
MooreB.M., SavdieR., PeBenitoR.A., HaynesA.M., MatthewsJ., DelpradoW., RasiahK.K., StrickerP.D.: The impact of nerve sparing on incidence and location of positive surgical margins in radical prostatectomy. BJU Int, 109: 533–538, 2012.
63.
SpinelliM.G., CozziG., GrassoA., TalsoM., VariscoD., Abed El RahmanD., AcquatiP., AlboG., RoccoB., MaggioniA., RoccoF.: RALP and Rocco stitch: original technique. Urologia, 78 Suppl 18: 35–38, 2011.
64.
DavisB.J., HorwitzE.M., LeeW.R., CrookJ.M., StockR.G., MerrickG.S., ButlerW.M., GrimmP.D., StoneN.N., PottersL., ZietmanA.L., ZelefskyM.J.; American Brachytherapy Society: American Brachytherapy Society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy. Brachytherapy, 11: 6–19, 2012.
65.
AshD., FlynnA., BattermannJ., de ReijkeT., LavagniniP., BlankL.; ESTRA/EAU Urological Brachytherapy Group; EORTC Radiotherapy Group: ESTRO/EAU/EORTC recommendations on permanent seed implantation for localized prostate cancer. Radiother Oncol, 57: 315–321, 2000.
66.
SalembierC., LavagniniP., NickersP., MangiliP., RijndersA., PoloA., VenselaarJ., HoskinP.; GEC ESTRO PROBATE Group: Tumour and target volumes in permanent prostate brachytherapy: a supplement to the ESTRO/EAU/EORTC recommendations on prostate brachytherapy. Radiother Oncol, 83: 3–10, 2007.
67.
ZelefskyM.J., ChanH., HuntM., YamadaY., ShippyA.M., AmolsH.: Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer. J Urol, 176: 1415–1419, 2006.
68.
ZelefskyM.J., KubanD.A., LevyL.B., PottersL., BeyerD.C., BlaskoJ.C., MoranB.J., CiezkiJ.P., ZietmanA.L., PisanskyT.M., ElshaikhM., HorwitzE.M.: Multi-institutional analysis of long-term outcome for stages T1(T2) prostate cancer treated with permanent seed implantation. Int J Radiat Oncol Biol Phys, 67: 327–333, 2007.
69.
MorrisW.J., KeyesM., PalmaD., SpadingerI., McKenzieM.R., AgranovichA., PicklesT., LiuM., KwanW., WuJ., BertheletE., PaiH.: Population-based study of biochemical and survival outcomes after permanent 125I brachytherapy for low- and intermediate-risk prostate cancer. Urology, 73: 860–867, 2009.
70.
HinnenK.A., JanJ.B., van RoermundJ.G., MoerlandM.A., Jürgenliemk-SchulzI.M., FrankS.J., van VulpenM.: Long-term biochemical and survival outcome of 921 patients treated with I-125 permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys, 76: 1433–1438, 2010.
ZelefskyM.J., YamadaY., PeiX., HuntM., CohenG., ZhangZ., ZaiderM.: Comparison of tumor control and toxicity outcomes of high-dose intensity-modulated radiotherapy and brachytherapy for patients with favorable risk prostate cancer. Urology, 77: 986–993, 2011.
75.
HunterG.K., ReddyC.A., KleinE.A., KupelianP., AngermeierK., UlchakerJ., ChehadeN., AltmanA., CiezkiJ.P.: Long-term (10-year) gastrointestinal and genitourinary toxicity after treatment with external beam radiotherapy, radical prostatectomy, or brachytherapy for prostate cancer. Prostate Cancer, doi: 10.1155/2012/853487, 2012.
76.
KleinE.A., CiezkiJ., KupelianP.A., MahadevanA.: Outcomes for intermediate risk prostate cancer: are there advantages for surgery, external radiation, or brachytherapy?Urol Oncol, 27: 67–71, 2009.
MohammedN., KestinL., GhilezanM., KraussD., ViciniF., BrabbinsD., GustafsonG., YeH., MartinezA.: Comparison of acute and late toxicities for three modern high-dose radiation treatment techniques for localized prostate cancer. Int J Radiat Oncol Biol Phys, 82: 204–212, 2012.
79.
ChiumentoC., MontagnaA., ClementeS., CozzolinoM., FuscoV.: A retrospective analysis after low-dose rate prostate brachytherapy with permanent 125I seed implant: clinical and dosimetric results in 70 patients. Tumori, 97: 335–340, 2011.
80.
ChiumentoC., FiorentinoA., CozzolinoM., CaivanoR., ClementeS., PediciniP., FuscoV.: Impact of comorbidity in elderly prostate cancer patients treated with brachytherapy. Chin J Cancer Res, 25: 274–280, 2013.
81.
GuarneriA., BotticellaA., FilippiA.R., MunozF., BeltramoG., CasettaG., GiglioliF.R., TizzaniA., RagonaR., RicardiU.: 125I brachytherapy for localized prostate cancer: a single institution experience. Tumori, 99: 83–87, 2013.
82.
MaggioA., PanaiaR., GaribaldiE., BrescianiS., MalinverniG., StasiM., GabrieleP.: Impact of age at diagnosis on overall and disease-free survival in men with prostate cancer following conformal 3D radiation therapy. Tumori, 98: 722–727, 2012.
83.
TramacereF., GianicoloE.A., PignatelliA., PortaluriM.: High-dose 3D-CRT in the radical and postoperative setting for prostate cancer. Analysis of survival and late rectal and urinary toxicity. Tumori, 98: 337–343, 2012.
84.
FowlerJ., ChappelR., RitterM.: Is alpha/beta for prostate tumors really low?Int J Radiat Oncol Biol Phys, 50: 1021–1031, 2001.
85.
BrennerD.J., MartinezA.A., EdmundsonG.K., MitchellC., ThamesH.D., ArmourE.P.: Direct evidence that prostate tumors shows high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue. Int J Radiat Oncol Biol Phys, 52: 6–13, 2002.
86.
WilliamsS.G., TaylorJ.M., LiuN., TraY., DuchesneG.M., KestinL.L., MartinezA., PrattG.R., SandlerH.: Use of individual fraction size data from 3756 patients to directly determine the alpha/beta ratio of prostate cancer. Int J Radiat Oncol Biol Phys, 68: 24–33, 2007.
87.
PediciniP., StrigariL., BenassiM.: Estimation of a self-consistent set of radiobiological parameters from hypofractionated versus standard radiation therapy of prostate cancer. Int J Radiat Oncol Biol Phys, 85: e231–237, 2013.
88.
LukkaH., HayterC., JulianJ.A., WardeP., MorrisW.J., GospodarowiczM., LevineM., SathyaJ., ChooR., PrichardH., BrundageM., KwanW.: A randomized trial comparing two fractionation schedules for patients with localized prostate cancer. J Clin Oncol, 23: 6132–6138, 2005.
89.
YeohE.E., BottenR.J., ButtersJ., Di MatteoA.C., HollowayR.H., FowlerJ.: Hypofractionated versus conventionally fractionated radiotherapy for prostate carcinoma: final results of phase III randomized trial. Int J Radiat Oncol Biol Phys, 81: 1271–1278, 2011.
90.
KubanD.A., Nogueras-GonzalezN.G., HamblinL., LeeA.K., ChoiS., FrankS.J., NguyenQ.N., HoffmanK.E., McGuireS.E., MunsellM.F.: Preliminary report of a randomized dose escalation trial for prostate cancer using hypofractionation. Int J Radiat Oncol Biol Phys, 78(suppl): S58, 2010.
91.
PollackA.W., WalkerG., BuyyounouskiM., HorwitzE., PriceR., FeigenbergS., KonskiA., StoyanovaR., MaC.: Five year results of a randomized external beam radiotherapy hypofractionation trial for prostate cancer. Int J Radiat Oncol Biol Phys, 81(suppl): S1, 2011.
92.
ArcangeliS., StrigariL., GomelliniS., SaracinoB., PetrongariM.G., PinnaròP., PinziV., ArcangeliG.: Updated results and pattern of failures in a randomized hypofractionation trial for high-risk prostate cancer. Int J Radiat Oncol Biol Phys, 84: 1172–1178, 2012.
ZeriniD., Jereczek-FossaB.A., VavassoriA., Bossi-ZanettiI., MauroR., IvaldiG.B., TrovòM., CambriaR., GaribaldiC., CattaniF., OrecchiaR.: 3D-conformal hypofractionated radiotherapy for prostate cancer with daily transabdominal ultrasonography prostate localization: toxicity and outcome of a pilot study. Tumori, 96: 941–946, 2010.
96.
ZumstegZ.S., ZelefskyM.J.: Short-term androgen deprivation therapy for patients with intermediate-risk prostate cancer undergoing dose-escalated radiotherapy: the standard of care?Lancet Oncol, 13: e259–269, 2012.
97.
JonesC.U., HuntD., McGowanD.G., AminM.B., ChetnerM.P., BrunerD.W., LeibenhautM.H., HusainS.M., RotmanM., SouhamiL., SandlerH.M., ShipleyW.U.: Radiotherapy and short-term androgen deprivation for localized prostate cancer. N Engl J Med, 365: 107–118, 2011.
98.
D'AmicoA.V., ChenM.H., RenshawA.A., LoffredoM., KantoffP.W.: Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA, 299: 289–295, 2008.
99.
DenhamJ.W., SteiglerA., LambD.S., JosephD., TurnerS., MatthewsJ., AtkinsonC., NorthJ., ChristieD., SpryN.A., TaiK.H., WynneC., D'EsteC.: Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial. Lancet Oncol, 12: 451–459, 2011.
LaverdièreJ., NabidA., De BedoyaL.D., EbacherA., FortinA., WangC.S., HarelF.: The efficacy and sequencing of a short course of androgen suppression on freedom from biochemical failure when administered with radiation therapy for T2–T3 prostate cancer. J Urol, 171: 1137–1140, 2004.
102.
KimM.M., HoffmanK.E., LevyL.B., FrankS.J., PughT.J., ChoiS., NguyenQ.N., McGuireS.E., LeeA.K., KubanD.A.: Prostate cancer-specific mortality after definitive radiation therapy: who dies of disease?Eur J Cancer, 48: 1664–1671, 2012.
103.
DubrayB.M., BeckendorfV., GuerifS., Le PriseE., Reynaud-BougnouxA., Hannoun LeviJ.M., NguyenT.D., HennequinC., CretinJ., Fayolle-CampanaM., LagrangeJ., BachaudJ., AzriaD., GrangirardA., PommierP., SimonJ., HarterV., HabibianM.: Does short-term androgen depletion add to high-dose radiotherapy (80 Gy) in localized intermediate-risk prostate cancer? Intermediate analysis of GETUG 14 randomized trial (EU-20503/NCT00104741). Proc Am Soc Clin Oncol, 29(suppl): 4521(abstr), 2011.
104.
ZelefskyM.J., PeiX., ChouJ.F., SchechterM., KollmeierM., CoxB., YamadaY., FidaleoA., SperlingD., HappersettL., ZhangZ.: Dose escalation for prostate cancer radiotherapy: predictors of long-term biochemical tumor control and distant metastases-free survival outcomes. Eur Urol, 60: 1133–1139, 2011.
105.
KubanD.A., LevyL.B., CheungM.R., LeeA.K., ChoiS., FrankS., PollackA.: Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer. Who dies of disease? Int J Radiat Oncol Biol Phys, 79: 1310–1317, 2011.
106.
HorwitzE.M., BaeK., HanksG.E., PorterA., GrignonD.J., BreretonH.D., VenkatesanV., LawtonC.A., RosenthalS.A., SandlerH.M., ShipleyW.U.: Ten-year follow-up of radiation therapy oncology group protocol 92–02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol, 26: 2497–2504, 2008.
107.
BollaM., Van TienhovenG., WardeP., DuboisJ.B., MirimanoffR.O., StormeG., BernierJ., KutenA., SternbergC., BillietI., TorecillaJ.L., PfefferR., CutajarC.L., Van der KwastT., ColletteL.: External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomized study. Lancet Oncol, 11: 1066–1073, 2010.
108.
BollaM., de ReijkeT.M., Van TienhovenG., Van den BerghA.C., OddensJ., PoortmansP.M., GezE., KilP., AkdasA., SoeteG., KariakineO., van der Steen-BanasikE.M., MusatE., Pié-rartM., MauerM.E., ColletteL.; EORTC Radiation Oncology Group and Genito-Urinary Tract Cancer Group: Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med, 360: 2516–2527, 2009.
109.
PilepichM.V., WinterK., LawtonC.A., KrischR.E., WolkovH.B., MovsasB., HugE.B., AsbellS.O., GrignonD.: Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma — long-term results of phase III RTOG 85–31. Int J Radiat Oncol Biol Phys, 61: 1285–1290, 2005.
KupelianP.A., ElshaikhM., ReddyC.A., ZippeC., KleinE.A.: Comparison of the efficacy of local therapies for localized prostate cancer in the prostate-specific antigen era: a large single-institution experience with radical prostatectomy and external-beam radiotherapy. J Clin Oncol, 20: 3376–3385, 2002.
112.
BollaM., van PoppelH., TombalB., VekemansK., Da PozzoL., de ReijkeT.M., VerbaeysA., BossetJ.F., van VelthovenR., ColombelM., van de BeekC., VerhagenP., van den BerghA., SternbergC., GasserT., van TienhovenG., ScallietP., HaustermansK., ColletteL.; European Organisation for Research and Treatment of Cancer, Radiation Oncology and Genito-Urinary Groups: Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). Lancet, 380: 2018–2027, 2012.
113.
ThompsonI.M., TangenC.M., ParadeloJ., LuciaM.S., MillerG., TroyerD., MessingE., FormanJ., ChinJ., SwansonG., Canby-HaginoE., CrawfordE.D.: Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term follow-up of a randomized clinical trial. J Urol, 181: 956–962, 2009.
114.
WiegelT., BottkeD., SteinerU., SiegmannA., GolzR., StörkelS., WillichN., SemjonowA., SouchonR., StöckleM., RübeC., WeissbachL., AlthausP., RebmannU., KälbleT., FeldmannH.J., WirthM., HinkeA., HinkelbeinW., MillerK.: Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol, 27: 2924–2930, 2009.
115.
AlongiF., CozzariniC., Di MuzioN., ScorsettiM.: Postoperative radiotherapy in prostate cancer: acquired certainties and still open issues. A review of recent literature. Tumori, 97: 1–8, 2011.
116.
KingC.R.: The timing of salvage radiotherapy after radical prostatectomy: a systematic review. Int J Radiat Oncol Biol Phys, 84: 104–111, 2012.
117.
OhriN., DickerA.P., TrabulsiE.J., ShowalterT.N.: Can early implementation of salvage radiotherapy for prostate cancer improve the therapeutic ratio? A systematic review and regression meta-analysis with radiobiological modelling. Eur J Cancer, 48: 837–844, 2012.
118.
Jereczek-FossaB.A., BeltramoG., FariselliL., FodorC., SantoroL., VavassoriA., ZeriniD., GherardiF., AscioneC., Bossi-ZanettiI., MauroR., BregantinA., BianchiL.C., De CobelliO., OrecchiaR.: Robotic image-guided stereotactic radiotherapy, for isolated recurrent primary, lymph node or metastastic prostate cancer. Int J Radiat Oncol Biol Phys, 82: 889–897, 2012.
119.
RicchettiF., BarraS., AgostinelliS., VaggeS., MarcenaroM., CorvòR.: Feasibility of helical tomotherapy for radical dose retreatment in pelvic area: a report of 4 cases. Tumori, 97: 492–497, 2011.
LoeningS.A., TurnerJ.W.: Use of percutaneous transperineal 198Au seeds to treat recurrent prostate adenocarcinoma after failure of definitive radiotherapy. Prostate, 23: 283–290, 1993.
122.
NguyenP.L., ChenM.H., D'AmicoA.V., TempanyC.M., SteeleG.S., AlbertM., CormackR.A., Carr-LockeD.L., BledayR., SuhW.W.: Magnetic resonance image-guided salvage brachytherapy after radiation in select men who initially presented with favorable-risk prostate cancer: a prospective phase 2 study. Cancer, 110: 1485–1492, 2007.
123.
KoutrouvelisP., HendricksF., LailasN., Gil-MonteroG., SehnJ., KhawandN., BondyH., KatzS.: Salvage reimplantation in patient with local recurrent prostate carcinoma after brachytherapy with three-dimensional computed tomography-guided permanent pararectal implant. Technol Cancer Res Treat, 2: 339–344, 2003.
124.
BeyerD.C.: Permanent brachytherapy as salvage treatment for recurrent prostate cancer. Urology, 54: 880–883, 1999.
125.
WongW.W., BuskirkS.J., SchildS.E., PrussakK.A., DavisB.J.: Combined prostate brachytherapy and short-term androgen deprivation therapy as salvage therapy for locally recurrent prostate cancer after external beam irradiation. J Urol, 176: 2020–2024, 2006.
126.
MomanM.R., van der PoelH.G., BattermannJ.J., MoerlandM.A., van VulpenM.: Treatment outcome and toxicity after salvage 125-I implantation for prostate cancer recurrences after primary 125-I implantation and external beam radiotherapy. Brachytherapy, 9: 119–125, 2010.
127.
BurriR.J., StoneN.N., UngerP., StockR.G.: Long-term outcome and toxicity of salvage brachytherapy for local failure after initial radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys, 77: 1338–1344, 2010.
128.
GradoG.L., CollinsJ.M., KriegshauserJ.S., BalchC.S., GradoM.M., SwansonG.P., LarsonT.R., WilkesM.M., NavickisR.J.: Salvage brachytherapy for localized prostate cancer after radiotherapy failure. Urology, 53: 2–10, 1999.
129.
HsuC.C., HsuH., PickettB., CrehangeG., HsuI.C., DeaR., WeinbergV., GottschalkA.R., KurhanewiczJ., ShinoharaK., RoachM3rd: Feasibility of MR imaging/MR spectroscopy-planned focal partial salvage permanent prostate implant (PPI) for localized recurrence after initial PPI for prostate cancer. Int J Radiat Oncol Biol Phys, 85: 370–377, 2013.
130.
JoY., FujiiT., HaraR., YokoyamaT., MiyajiY., YodenE., HiratsukaJ., NagaiA.: Salvage high-dose-rate brachytherapy for local prostate cancer recurrence after radiotherapy - preliminary Results. BJU Int, 109: 835–839, 2012.
131.
LeeB., ShinoharaK., WeinbergV., GottschalkA.R., PouliotJ., RoachM3rd, HsuI.C.: Feasibility of high-dose-rate brachytherapy salvage for local prostate cancer recurrence after radiotherapy: the University of California - San Francisco experience. Int J Radiat Oncol Biol Phys, 67: 1106–1112, 2007.
132.
EngelsB., SoeteG., TournelK., BralS., De ConinckP., VerellenD., StormeG.: Helical tomotherapy with simultaneous integrated boost for high-risk and lymph node-positive prostate cancer: early report on acute and late toxicity. Technol Cancer Res Treat, 8: 353–359, 2009.
CasamassimaF., MasiL., MenichelliC., BonucciI., CasamassimaE., LazzeriM., GulisanoM., AteriniS.: Efficacy of eradicative radiotherapy for limited nodal metastases detected with choline PET scan in prostate cancer patients. Tumori, 97: 49–55, 2011.
135.
RigattiP., SuardiN., BridantiA., Da PozzoL.F., TutoloM., VillaL., GallinaA., CapitanioU., AbdollahF., ScattoniV., ColomboR., FreschiM., PicchioM., MessaC., GuazzoniG., MontorsiF.: Pelvic/retroperitoneal salvage lymph node dissection for patients treated with radical prostatectomy with biochemical recurrence and nodal recurrence detected by [11C]choline positron emission tomography/computed tomography. Eur Urol, 60: 935–943, 2011.
136.
PetrylakD.P., TangenC.M., HussainM.H., LaraP.N.Jr., JonesJ.A., TaplinM.E., BurchP.A., BerryD., MoinpourC., KohliM., BensonM.C., SmallE.J., RaghavanD., CrawfordE.D.: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med, 351: 1513–1520, 2004.
137.
TannockI.F., de WitR., BerryW.R., HortiJ., PluzanskaA., ChiK.N., OudardS., ThéodoreC., JamesN.D., TuressonI., RosenthalM.A., EisenbergerM.A.; TAX 327 Investigators: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med, 351: 1502–1512, 2004.
138.
MassariF., MainesF., ModenaA., BrunelliM., BriaE., ArtibaniW., MartignoniG., TortoraG.: Castration resistant prostate cancer (CRPC): state of the art, perspectives and new challenges. Anticancer Agents Med Chem, 13: 872–886, 2013.
RyanC.J., SmithM.R., de BonoJ.S., MolinaA., LogothetisC.J., de SouzaP., FizaziK., MainwaringP., PiulatsJ.M., NgS., CarlesJ., MuldersP.F., BaschE., SmallE.J., SaadF., SchrijversD., Van PoppelH., MukherjeeS.D., SuttmannH., GerritsenW.R., FlaigT.W., GeorgeD.J., YuE.Y., EfstathiouE., PantuckA., WinquistE., HiganoC.S., TaplinM.E., ParkY., KheohT., GriffinT., ScherH.I., RathkopfD.E.; COU-AA-302 Investigators: Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med, 368: 138–148, 2013.
141.
ScherH.I., FizaziK., SaadF., TaplinM.E., SternbergC.N., MillerK., De WitR., MuldersP, HirmandM., SelbyB., De BonoJ.S., for the AFFIRM Investigators: Effect of MDV3100, an androgen receptor signaling inhibitor (ARSI), on overall survival in patients with prostate cancer postdocetaxel: Results from the phase III AFFIRM study. J Clin Oncol, 30(5 Suppl): LBA1, 2012.
142.
GeorgeD., MoulJ.W.: Emerging treatment options for patients with castration-resistant prostate cancer. Prostate, 72: 338–349, 2012.
143.
SmallE.J., SchellhammerP.F., HiganoC.S., RedfernC.H., NemunaitisJ.J., ValoneF.H., VerjeeS.S., JonesL.A., HershbergR.M.: Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol, 24: 3089–3094, 2006.
144.
HiganoC.S., SchellhammerP.F., SmallE.J., BurchP.A., NemunaitisJ., YuhL., ProvostN., FrohlichM.W.: Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer, 115: 3670–3679, 2009.
145.
KantoffP.W., HiganoC.S., ShoreN.D., BergerE.R., SmallE.J., PensonD.F., RedfernC.H., FerrariA.C., DreicerR., SimsR.B., XuY., FrohlichM.W., SchellhammerP.F.; IMPACT Study Investigators: Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med, 363: 411–422, 2010.
